**Highlights of This Issue** 937

**Special Features**

**CCR 20th Anniversary Commentary**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>939</td>
<td>CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341</td>
<td>Beverly A. Teicher and Kenneth C. Anderson</td>
</tr>
</tbody>
</table>

**CCR Translations**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>944</td>
<td>Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better</td>
<td>Roxana S. Dronca and Haidong Dong</td>
</tr>
<tr>
<td></td>
<td><em>See related articles, p. 1115 and p. 1127</em></td>
<td></td>
</tr>
<tr>
<td>947</td>
<td>Moving from Evaluation to Value in Cancer Care</td>
<td>Richard L. Schilsky</td>
</tr>
<tr>
<td></td>
<td><em>See related article, p. 1036</em></td>
<td></td>
</tr>
</tbody>
</table>

**CCR Perspectives in Drug Approval**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>950</td>
<td>FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease</td>
<td>Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F. Zirkelbach, Liang Zhao, Julie Bullock, Nitin Mehrotra, Pedro Del Valle, Haleh Saber, Christopher Sheth, Brenda Gehrzke, Robert Justice, Ann Farrell, and Richard Pazdur</td>
</tr>
</tbody>
</table>

**Molecular Pathways**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>955</td>
<td>Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer</td>
<td>Rebecca A. Paevis, Robert L. Coleman, Adrian L. Harris, and Anil K. Sood</td>
</tr>
<tr>
<td>962</td>
<td>Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis</td>
<td>Hae-Yun Jung, Laurent Fattet, and Jing Yang</td>
</tr>
<tr>
<td>969</td>
<td>Zebrfish: A New Companion for Translational Research in Oncology</td>
<td>Jorge Barriuso, Rahavendr Nagaraju, and Adam Hurlstone</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>995</td>
<td>CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment</td>
<td>Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gramlich, Maryann Gallagher, Priti Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer, Noah Goodman, Susan Domchek, Kerrihi Gogineni, Mark Rosen, Kevin Fox, and Peter O’Dwyer</td>
</tr>
</tbody>
</table>
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James C. Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi-Chia R. Lee, Yong F. Li, Mona El-Gamil, and Steven A. Rosenberg

Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg, David G. McFadden, Edwin L. Palmer, Gilbert H. Daniels, and Lori J. Wirth

Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors
Alberto F. Sobrero, Alessandro Pastorino, Daniel J. Sargent, and Paolo Bruzzi

A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Andrew J. Wagner, Wells A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, and Anthony B. El-Khoueiry

Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer

LONGITUDINAL NONINVASIVE IMAGING OF PROGESTERONE RECEPTOR AS A PREDICTIVE BIOMARKER OF TUMOR RESPONSIVENESS TO ESTROGEN DEPRIVATION THERAPY
Sezeman Ruby Chan, Amy M. Fowler, Julie A. Allen, Dong Zhou, Carmen S. Dence, Terry L. Sharp, Nicole M. Fettig, Farrokh Dehdashti, and John A. Katzenellenbogen

CORRELATION OF PD-L1 TUMOR EXPRESSION AND TREATMENT OUTCOMES IN PATIENTS WITH RENAL CELL CARCINOMA RECEIVING SUNITINIB OR PAZOPANIB: RESULTS FROM COMPARZ, A RANDOMIZED CONTROLLED TRIAL
Toni K. Choueiri, David J. Figueroa, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, and Robert J. Motzer

GENE EXPRESSION MARKERS OF EFFICACY AND RESISTANCE TO CETUXIMAB TREATMENT IN METASTATIC COLORECTAL CANCER: RESULTS FROM CALGB 80203 (ALLIANCE)
Stephanie M. Cushman, Chen Jiang, Ace I. Hatch, Ivo Shcheyev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kouros Owzar, Herbert I. Hurwitz, and Andrew B. Nixon

CLINICAL RELEVANCE OF KRAS-MUTATED SUBCLONES DETECTED WITH PICRODROPLET DIGITAL PCR IN ADVANCED COLORECTAL CANCER TREATED WITH ANTI-EGFR THERAPY
Pierre Laurent-Puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos, Philippe Nizard, Karla Perez-Toralla, Rachel Rowell, Jeff Olson, Preethi Sriivasan, Delphine Le Corre, Theyy Hor, Zakaria El Harrak, Xinyu Li, Darren R. Link, Olivier Boucê, Jean-François Emile, Bruno Landi, ValérieBoige, J. Brian Hutchinson, and Valerie Taly

NEUREGULIN 1 EXPRESSION IS A PREDICTIVE BIOMARKER FOR RESPONSE TO AV-203, AN ERBB3 INHIBITORY ANTIBODY, IN HUMAN TUMOR MODELS
Kristan Meetze, Sylvie Vincent, Steven Tyler, Elizabeth K. Maza, Andrea R. Delpiero, Steve Bottega, Donna McIntosh, Richard Nicoletti, William M. Winston, Sally Weiler, Bin Feng, Jeno Gyuris, and Zhigang Weng

THE HUMAN AGONISTIC CD40 ANTIBODY ADC-1013 ERADICATES BLADDER TUMORS AND GENERATES T-cell–DEPENDENT TUMOR IMMUNITY
Sara M. Mangsbo, Sissela Broos, Erika Fletcher, Nīnā Veičienė, Christina Furebring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H. Tötterman, and Peter Ellmark

See related commentary, p. 944
Table of Contents

1127  Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, and Karl Erik Hellstrom
See related commentary, p. 944

1139  Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing’s Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Min H. Kang, Jing Wang, Monish R. Makena, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael M. Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle, Winford Ko, Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. Triche, and C. Patrick Reynolds

1151  Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

1161  Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changyong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, and Mala Shanmugam

1172  Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy

1183  Integrinβ6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma
Benjia Liang, Muhammad Shahbaz, Yang Wang, Huijie Gao, Ruliang Fang, Zhengchuan Niu, Song Liu, Ben Wang, Qi Sun, Weibo Niu, Enyu Liu, Bayong Wang, and Jun Niu

BIOLOGY OF HUMAN TUMORS

1196  Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Andrew Feber, Manit Arya, Patricia de Winter, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Matthias Lechner, Alex Freeman, Charles Jameson, Asif Muneer, Stephan Beck, and John D. Kelly

1207  A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Kristine Kleivi Sahlberg, Giulia Bottai, Bjorn Naume, Barbara Burwinkel, George A. Calin, Anne-Lise Berresen-Dale, and Libero Santarpia

1215  Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Raphael Maréchal, Jean-Baptiste Bachel, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Svcek, Jérôme Cros, Armelle Bardier-Dupas, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Treut, Jean-Christophe Vaillant, Alain Sauvanet, Thierry André, Isabelle Salmon, Jacques Devière, Jean-François Emile, and Jean-Luc Van Laethem

1225  Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Xin Zhang, Xiaoyun Yang, Yanli Zhang, Xinfeng Liu, Guixi Zheng, Yongmei Yang, Lili Wang, Lutao Du, and Chuanxin Wang

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org

vi
ABOUT THE COVER

The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.